[HTML][HTML] Efficacy of Molnupiravir for the treatment of mild or moderate COVID-19 in adults: a meta-analysis

K Benaicha, RR Khenhrani, M Veer, S Devi… - Cureus, 2023 - ncbi.nlm.nih.gov
The aim of this meta-analysis is to evaluate the efficacy of molnupiravir among mild or
moderate COVID-19 patients. This meta-analysis was reported according to the guidelines …

Real-world clinical outcomes of molnupiravir for the treatment of mild to moderate COVID-19 in adult patients during the dominance of the Omicron variant: a meta …

C Huang, TL Lu, L Lin - Antibiotics, 2023 - mdpi.com
Introduction: The therapeutic impact of molnupiravir in the Omicron variant phase is
unknown. The goal of the current meta-analysis was to compare the real-world clinical …

Effectiveness, tolerability and prescribing choice of antiviral molecules molnupiravir, remdesivir and nirmatrelvir/r: a real-world comparison in the first ten months of use

C Del Borgo, S Garattini, C Bortignon, A Carraro… - Viruses, 2023 - mdpi.com
In 2022, three antiviral drugs—molnupiravir, remdesivir and nirmatrelvir/ritonavir—were
introduced for treatment of mild-to-moderate COVID-19 in high-risk patients. The aim of this …

Experimental and theoretical study on supramolecular encapsulation of molnupiravir by Cucurbit [7] uril: A potential formulating agent for COVID-19

S Sen, N Baildya, M Alphonse-Mendoza… - Journal of Molecular …, 2024 - Elsevier
Global propagation of the Novel Coronavirus Diseases-2019 (COVID-19) outbreak
threatens the scientific community's ability to develop and learn effective SARS-CoV-2 …

Adverse events associated with molnupiravir: a real-world disproportionality analysis in food and drug administration adverse event reporting system

Y Liang, L Ma, Y Wang, J Zheng, L Su… - Frontiers in …, 2023 - frontiersin.org
Molnupiravir, an urgently approved drug during the Coronavirus Disease 2019 (COVID-19)
pandemic, serves as the basis for our study, which relies on the Food and Drug …

Molnupiravir Revisited—Critical Assessment of Studies in Animal Models of COVID-19

HB Rasmussen, PR Hansen - Viruses, 2023 - mdpi.com
Molnupiravir, a prodrug known for its broad antiviral activity, has demonstrated efficacy in
animal models of COVID-19, prompting clinical trials, in which initial results indicated a …

Molnupiravir, a ribonucleoside antiviral prodrug against SARS-CoV-2, alters the voltage-gated sodium current and causes adverse events

AL Shiau, KH Lee, HY Cho, TH Chuang, MC Yu… - Virology, 2023 - Elsevier
Molnupiravir (MOL) is a ribonucleoside prodrug for oral treatment of COVID-19. Common
adverse effects of MOL are headache, diarrhea, and nausea, which may be associated with …

[HTML][HTML] New conjugates based on N4-hydroxycytidine with more potent antiviral efficacy in vitro than EIDD-2801 against SARS-CoV-2 and other human …

AE Siniavin, VA Gushchin, SS Natal'ya, ES Darnotuk… - Antiviral Research, 2024 - Elsevier
The spread of COVID-19 continues due to genetic variation in SARS-CoV-2. Highly mutated
variants of SARS-CoV-2 have an increased transmissibility and immune evasion. Due to the …

Longitudinal study of disease severity and external factors in cognitive failure after COVID-19 among Indonesian population

B Herman, MCS Wong, P Chantharit, FF Hannanu… - Scientific Reports, 2023 - nature.com
The COVID-19 infection is assumed to induce cognitive failure. Identifying the relationship
between COVID-19, the effect of vaccination and medication, and accommodating non …

Molecular epidemiology of SARS-CoV-2 omicron sub-lineages isolated from Turkish patients infected with COVID-19

M Sayan, A Arikan, E Sanlidag - Viruses, 2023 - mdpi.com
Early detection and characterization of new variants and their impacts enable improved
genomic surveillance. This study aims to evaluate the subvariant distribution of Omicron …